Influenza trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Influenza. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month4 studies across 3 companies, in the next 180 days.
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| TRAW | Traws Pharma, Inc. | Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge ModelNCT07503405Laboratory-Confirmed Infection | Phase 2 | Not yet recruiting | Nov 2026 | ≤ 102 d | 2026-03-31 |
December 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| TRAW | Traws Pharma, Inc. | This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate InfluenzaNCT07371650Incidence of AE/SAE | Phase 2 | Active, not recruiting | Dec 2026 | ≤ 133 d | 2026-03-27 |
January 2027 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| MRNA | ModernaTX, Inc. | A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsNCT07496450Percentage of Participants With Hemagglutination Inhibition (HAI) Titer ≥ 1:40 at Day 43 | Phase 3 | Active, not recruiting | 2027-01-28 | in 161 d | 2026-08-11 |
| PFE | Pfizer | A Study to Look at the Health Outcomes of Patients With COVID-19 and InfluenzaNCT05160636observationalChange in Health Related Quality of Life (HRQoL) using EQ-5D-5L | — | Active, not recruiting | 2027-01-31 | in 164 d | 2026-03-31 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Influenza
most recently updated first134 studies match. Showing the first 100 of 134 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRNA | ModernaTX, Inc. | $25.1B | A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsNCT07496450Percentage of Participants With Hemagglutination Inhibition (HAI) Titer ≥ 1:40 at Day 43 | Phase 3 | Active, not recruiting | Biological: mRNA-1018-H5, Placebo | Influenza | 4,050 | 2026-03-23 | 2027-01-28 | in 161 d | 2026-08-11 |
| AZN | AstraZeneca | — | A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)NCT07128615Percentage of participants with immediate unsolicited adverse events (AE) | Phase 1/2 | Active, not recruiting | Biological: AZD4117, AZD5315 · Other: Placebo | Influenza A | 405 | 2025-09-04 | 2026-01-28actual | — | 2026-07-20 |
| PFE | Pfizer | $155.3B | A Study About Modified RNA Vaccines Against Influenza in Healthy AdultsNCT06436703results2026-06-12SSA: Percentage of Participants With Local Reactions for up to 7 Days Following Vaccination | Phase 1/2 | Completed | Biological: Influenza ModRNA Vaccine, Quadrivalent Influenza Vaccine (QIV) | Influenza, Human | 1,202 | 2024-05-23 | 2025-02-05actual | — | 2026-06-12 |
| BCRX | BioCryst Pharmaceuticals | $2.5B | A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.NCT01224795To evaluate the efficacy of peramivir administered intravenously compared to placebo on the time to alleviation of clinical symptoms with acute uncomplicated influenza. | Phase 3 | Withdrawn | Drug: Peramivir, Placebo Comparator | Influenza | 0 | Oct 2010 | Nov 2010actual | — | 2026-06-10 |
| BCRX | BioCryst Pharmaceuticals | $2.5B | Intramuscular Peramivir for the Treatment of Uncomplicated InfluenzaNCT00486980 | Phase 3 | Withdrawnsponsor's stated reason: This study was withdrawn for administrative reasons. The dose ranging plan for the program was revised". | Drug: Peramivir 150mg, Peramivir 300mg | Influenza | 0 | — | — | — | 2026-06-01 |
| SNY | Sanofi | — | Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and OlderNCT06695117Number of participants with immediate adverse events (AEs) | Phase 1/2 | Completed | Biological: IIV-HD, rC19 (dose 1), IIV-HD + rC19 (dose 1), IIV-HD + rC19 (dose 2), IIV-HD + rC19 (dose 3), IIV-HD + rC19 (dose 4) · Other: Placebo (0.9% NaCl) | COVID-19 Immunization, Influenza Immunization | 980 | 2024-11-19 | 2026-04-16actual | — | 2026-05-05 |
| SNY | Sanofi | — | Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and OlderNCT06695130Number of participants with immediate adverse events (AEs) | Phase 1/2 | Completed | Biological: RIV (recombinant influenza vaccine), rC19 (dose 1), RIV + rC19 (dose 1), RIV + rC19 (dose 2), RIV + rC19 (dose 3), RIV + rC19 (dose 4) · Other: Placebo (0.9% NaCl) | COVID-19 Immunization, Influenza Immunization | 980 | 2024-11-18 | 2026-04-03actual | — | 2026-05-05 |
| SNY | Sanofi | — | A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection QuestionnaireNCT06765187observationalProportion of Participants Reporting Incidence of Reactions (Local) Using Vaccinees' Perception of Injection (VAPI) Questionnaire (Age Groups [18-49 and 50-64 years]) | — | Completed | Biological: Trivalent Recombinant Influenza Vaccine | Influenza Immunization, Health Volunteers | 1,007 | 2024-11-18 | 2025-12-22actual | — | 2026-04-07 |
| ARCT | Arcturus Therapeutics, Inc. | $233M | Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in AdultsNCT06602531Percentage of participants reporting local Adverse Events | Phase 1 | Completed | Biological: ARCT-2304, Control vaccine (licensed seasonal influenza vaccine) younger adults, Control vaccine (licensed seasonal influenza vaccine) older adults · Other: Placebo Vaccine | Influenza, Human | 212 | 2024-12-10 | 2025-06-13actual | — | 2026-04-03 |
| PFE | Pfizer | $155.3B | A Study to Look at the Health Outcomes of Patients With COVID-19 and InfluenzaNCT05160636observationalChange in Health Related Quality of Life (HRQoL) using EQ-5D-5L | — | Active, not recruiting | Biological: COVID-19 Vaccine | COVID-19, Coronavirus Disease 2019, Influenza | 999 | 2022-01-31 | 2027-01-31 | in 164 d | 2026-03-31 |
| SNY | Sanofi | — | Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled SyringeNCT07282795observationalOccurrence of solicited injected site reactions. | — | Not yet recruiting | Biological: Efluelda® Pre-filled syringe | Influenza Immunization, Healthy Volunteers | 670 | 2026-10-01 | 2029-02-22 | in 917 d | 2026-03-31 |
| TRAW | Traws Pharma, Inc. | $8M | Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge ModelNCT07503405Laboratory-Confirmed Infection | Phase 2 | Not yet recruiting | Drug: TRX-100, Placebo · Biological: Influenza A/France/759/2021 (H1N1) virus | Influenza | 165 | Jun 2026 | Nov 2026 | ≤ 102 d | 2026-03-31 |
| TRAW | Traws Pharma, Inc. | $8M | This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate InfluenzaNCT07371650Incidence of AE/SAE | Phase 2 | Active, not recruiting | Drug: TRX-100, Standard of Care (SOC) | Influenza | 105 | 2025-12-15 | Dec 2026 | ≤ 133 d | 2026-03-27 |
| PFE | Pfizer | $155.3B | A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of InfluenzaNCT05227001Percentage of participants reporting local reactions | Phase 1 | Completed | Biological: PF-07852352 Influenza saRNA 1, PF-07836391 Influenza saRNA, PF-07836394 Influenza saRNA, PF-07836395 Influenza saRNA, PF-07836396 Influenza saRNA, PF-07867246 Influenza saRNA, Placebo, Quadrivalent influenza vaccine (QIV), PF-07871987 Influenza saRNA, PF-07914705 Influenza saRNA, PF-07915048 Influenza saRNA | Influenza, Human | 440 | 2022-04-28 | 2023-08-04actual | — | 2026-03-20 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study of Modified mRNA Vaccines in Healthy AdultsNCT05397223Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs) | Phase 1 | Completed | Biological: mRNA-1273, mRNA-1010, mRNA-1345, FLUAD®, mRNA-1647 | SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus | 308 | 2022-05-24 | 2026-02-27actual | — | 2026-03-12 |
| PFE | Pfizer | $155.3B | A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic InfluenzaNCT06179446Percentage of participants by age group reporting local reactions | Phase 1 | Completed | Biological: pdmFlu vaccine, Placebo, Licensed influenza vaccine | Grippe, Influenza, Vaccines | 157 | 2023-12-13 | 2025-09-23actual | — | 2026-02-23 |
| COCP | Cocrystal Pharma, Inc. | $21M | CC-42344 Safety Study in Healthy ParticipantsNCT05202379results2026-02-19Part 1 SAD: Number of Participants With Treatment-Emergent Adverse Events (TEAE) | Phase 1 | Completed | Drug: CC-42344, Placebo | Influenza A | 80 | 2022-02-11 | 2023-03-29actual | — | 2026-02-19 |
| BNTX | BioNTech SE | — | A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy PeopleNCT06821061Percentage of participants reporting prompted local reactions within 7 days following investigational product administration | Phase 1/2 | Completed | Biological: Investigational Influenza Vaccine, Investigational COVID-19 Vaccine, Licensed Influenza Vaccine 1, Licensed Influenza Vaccine 2, Licensed Influenza Vaccine 3, Licensed COVID-19 Vaccine · Combination product: Investigational Influenza and COVID-19 Combination Vaccine | Influenza, COVID-19 (Coronavirus Disease 2019) | 2,650 | 2025-02-10 | 2025-12-17actual | — | 2026-01-26 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy AdultsNCT05827926results2025-12-23Parts 1 and 2: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) | Phase 1/2 | Completed | Biological: Influenza Vaccine 1, mRNA-1083.1, mRNA-1083.2, mRNA-1083.3, Investigational Influenza Vaccine 1, Investigational COVID-19 Vaccine 1, COVID-19 Vaccine 1, Investigational Influenza Vaccine 2, Influenza Vaccine 2, mRNA-1083, Investigational COVID-19 Vaccine 2, COVID-19 Vaccine 2 | SARS-CoV-2, Influenza | 1,758 | 2023-04-14 | 2024-12-03actual | — | 2025-12-23 |
| BNTX | BioNTech SE | — | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.NCT06178991results2025-12-04Cohort 1: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination in Investigational Vaccine Extremity | Phase 3 | Completed | Biological: Influenza and COVID-19 Combination A, Licensed influenza vaccine, COVID-19 Vaccine, Influenza and COVID-19 Combination B, Placebo, Investigational influenza vaccine | Influenza, COVID-19 | 8,795 | 2023-12-20 | 2024-11-26actual | — | 2025-12-04 |
| MRNA | ModernaTX, Inc. | $25.1B | Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of AgeNCT06694389Geometric Mean (GM) Level of Antibodies for Influenza, as Measured by Hemagglutination Inhibition (HAI) Assay | Phase 3 | Completed | Biological: mRNA-1083, Licensed Influenza Vaccine, SARS-CoV-2 Vaccine · Other: Placebo | COVID-19, Influenza | 2,457 | 2024-11-18 | 2025-11-17actual | — | 2025-12-02 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy AdultsNCT05606965Parts A, B, and C: Number of Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs) | Phase 2 | Completed | Biological: mRNA-1010, Egg-based Quadrivalent Influenza Vaccine, Adjuvanted Quadrivalent Influenza Vaccine, Inactivated Influenza Vaccine, mRNA-1345, mRNA-1045 | Influenza | 172 | 2022-11-02 | 2025-11-13actual | — | 2025-11-24 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of AgeNCT06864143Geometric Mean Titer (GMT) as Measured by Hemagglutination Inhibition (HAI) Assay for Influenza | Phase 2 | Completed | Biological: mRNA-1083 Composition 1 Dose A Lot A, mRNA-1083 Composition 1 Dose A Lot B, mRNA-1083 Composition 1 Dose B, mRNA-1083 Composition 1 Dose C, mRNA-1083 Composition 2 Dose A, mRNA-1083 Composition 2 Dose B, mRNA-1083 Composition 3 Dose A, mRNA-1083 Composition 3 Dose B, Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza Vaccine, Investigational COVID-19 Vaccine Lot A, Investigational COVID-19 Vaccine Lot B | Influenza, SARS-CoV-2 | 1,320 | 2025-03-07 | 2025-10-13actual | — | 2025-10-20 |
| MRNA | ModernaTX, Inc. | $25.1B | A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)NCT06508320Geometric Mean Value of Antibodies at Day 29, as Measured by Hemagglutinin Inhibition (HAI) Assay for Influenza | Phase 2 | Completed | Biological: mRNA-1083 | Influenza, SARS-CoV-2 | 932 | 2024-07-15 | 2025-09-25actual | — | 2025-10-14 |
| ARCT | Arcturus Therapeutics, Inc. | $233M | Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in AdultsNCT06125691Percentage of participants reporting local Adverse Events | Phase 1 | Completed | Biological: ARCT-2138, Licensed Quadrivalent Vaccine for younger adults, Licensed Quadrivalent Vaccine for older adults | Influenza, Human | 139 | 2024-01-22 | 2024-08-10actual | — | 2025-10-03 |
| PFE | Pfizer | $155.3B | A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy AdultsNCT06237049results2025-09-30Percentage of Participants Who Reported Any Local Reaction up to 7 Days Following Vaccination | Phase 2 | Completed | Biological: BNT162b2 (Omi XBB.1.5)/RIV, BNT162b2 (Omi XBB.1.5), RIV · Other: Normal saline placebo | Influenza, Human, SARS-CoV-2 Infection, COVID-19 | 644 | 2024-01-31 | 2024-09-13actual | — | 2025-09-30 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of AgeNCT06602024Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) | Phase 3 | Completed | Biological: mRNA-1010, Fluarix®, Influsplit® Tetra, Fluarix Tetra, Alpharix® Tetra | Seasonal Influenza | 40,817 | 2024-09-16 | 2025-08-21actual | — | 2025-09-10 |
| COCP | Cocrystal Pharma, Inc. | $21M | Influenza Viral Challenge Study of CC-42344 in Healthy ParticipantsNCT06160531Area under the influenza viral load-time curve (VL-AUC) of influenza challenge virus | Phase 2 | Completed | Drug: CC-42344, Placebo | Influenza A | 78 | 2023-11-25 | 2024-05-03actual | — | 2025-08-05 |
| BNTX | BioNTech SE | — | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and InfluenzaNCT05596734results2025-07-23SSA: Percentage of Participants With Local Reactions up to 7 Days Following Vaccination (18-64 Years) | Phase 2 | Completed | Biological: bivalent BNT162b2 (original/Omi BA.4/BA.5), qIRV (22/23), QIV, bIRV, tIRV | Influenza, Human, COVID-19 | 1,019 | 2022-10-28 | 2023-12-28actual | — | 2025-07-23 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy AdultsNCT05972174Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) | Phase 1/2 | Completed | Biological: mRNA-1018 for H5N8, mRNA-1018 for H7N9, mRNA-1018 for H5 Only, mRNA-1018 for H7 Only, mRNA-1018 for H5 Only-CG | Influenza | 1,504 | 2023-07-10 | 2024-07-16actual | — | 2025-07-16 |
| MRNA | ModernaTX, Inc. | $25.1B | Study of mRNA-1010 Seasonal Influenza Vaccine in AdultsNCT05827978results2025-07-10Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibody Levels as Measured by Hemagglutination Inhibition (HAI) | Phase 3 | Completed | Biological: mRNA-1010, Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine | Seasonal Influenza | 8,411 | 2023-04-17 | 2024-06-24actual | — | 2025-07-10 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of AgeNCT06097273results2025-06-13Geometric Mean (GM) Level of Antibodies for Influenza, as Measured by Hemagglutination Inhibition (HAI) Assay | Phase 3 | Completed | Biological: mRNA-1083, Placebo, Influenza Vaccine, COVID-19 Vaccine | SARS-CoV-2, Influenza | 8,061 | 2023-10-19 | 2024-05-28actual | — | 2025-07-01 |
| ALT | Altimmune, Inc. | $578M | Study of the Safety and Immunogenicity of NasoVAX ExtensionNCT03760549observationalImmune response to NasoVAX when administered by intranasal spray at a single dose of 1×10(11th) vp after approximately 1year | — | Completed | Drug: Subjects were administered NasoVAX high dose | Influenza | 8 | 2019-01-21 | 2019-02-18actual | — | 2025-06-19 |
| PFE | Pfizer | $155.3B | A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or OlderNCT05540522results2025-05-08Percentage of Participants Reporting First Episode of LCI Cases With Associated Per-Protocol ILI Caused by Any Strain at Least 14 Days After Vaccination: 18-64 Years | Phase 3 | Completed | Biological: Quadrivalent influenza modRNA vaccine, Quadrivalent influenza vaccine | Influenza, Human | 45,789 | 2022-09-12 | 2024-03-12actual | — | 2025-05-08 |
| AZN | AstraZeneca | — | Uptake of the Childhood Live Attenuated Influenza Vaccine (LAIV) and Influenza-related Healthcare Resource Use in England During the 2012 to 2022 Flu Seasons; a Retrospective, Observational Study in the CPRD and HES DatabasesNCT06077045observationalUptake of influenza vaccination | — | Completed | — | Influenza | 12,775,880 | 2023-01-18 | 2023-07-04actual | — | 2025-04-27 |
| ADM | The Archer-Daniels-Midland Company | $39.7B | Study to Assess the Effect of Multistrain Probiotic on the Immune Response to the Influenza VaccinationNCT06103994Change in serum strain-specific geometric mean antibody titers (determined by hemagglutination inhibition [HAI] tests) | Not applicable | Completed | Dietary supplement: Multistrain probiotic · Other: Placebo | Influenza | 120 | 2023-10-27 | 2024-01-12actual | — | 2025-04-10 |
| NVAX | Novavax | $1.3B | Lot Consistency Study of COVID-19 and Influenza Combination VaccineNCT06482359Numbers of participants with solicited local and systemic AEs. | Phase 2/3 | Withdrawnsponsor's stated reason: It was decided to not move forward with the study. | Biological: coformulated CIC Vaccine, Fluzone HD trivalent | COVID-19, Influenza | 0 | 2025-02-01 | 2025-11-16 | — | 2025-03-11 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy AdultsNCT05827068results2025-02-03Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) | Phase 1/2 | Completed | Biological: mRNA-1011.1, mRNA-1011.2, mRNA-1012.1, mRNA-1010, mRNA-1010.2, mRNA-1010.3 | Seasonal Influenza | 698 | 2023-03-27 | 2023-11-20actual | — | 2025-02-03 |
| SABS | SAb Biotherapeutics, Inc. | $345M | Study of SAB-176 in Healthy Adult ParticipantsNCT04850898results2025-01-22To Evaluate Viral Load by Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR) of SAB-176 When Compared to Placebo | Phase 2 | Completed | Biological: SAB-176 · Other: Placebo | Influenza A H1N1 | 62 | 2021-06-23 | 2021-10-08actual | — | 2025-01-22 |
| EBS | Emergent BioSolutions | $239M | Universal Influenza A Vaccine in Healthy AdultsNCT05155319Safety of the UFluA vaccine following one of four dose schedules as evaluated through adverse events (AEs), serious adverse events (SAEs), adverse events of special interest (AESIs) and medically attended adverse events (MAAEs). | Phase 1 | Completed | Biological: UFluA 20 µg each antigen/dose, UFluA 60 µg each antigen/dose, Placebo | Human Influenza | 27 | 2021-12-01 | 2023-10-10actual | — | 2025-01-20 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and OlderNCT05566639results2025-01-16Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs) | Phase 3 | Completed | Biological: mRNA-1010, Fluarix Quadrivalent | Seasonal Influenza | 22,502 | 2022-09-14 | 2024-01-05actual | — | 2025-01-16 |
| SABS | SAb Biotherapeutics, Inc. | $345M | Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy ParticipantsNCT04471038results2025-01-06Number of Participants Having Adverse Events | Phase 1 | Completed | Biological: SAB-176 · Other: Normal Saline | Influenza Type A, Influenza Type B, Influenza | 27 | 2020-07-29 | 2021-04-19actual | — | 2025-01-06 |
| MRNA | ModernaTX, Inc. | $25.1B | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy AdultsNCT05868382results2024-12-20Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) | Phase 2 | Completed | Biological: mRNA-1010, mRNA-1010.4, mRNA-1010.6 | Influenza | 270 | 2023-05-15 | 2023-12-19actual | — | 2024-12-20 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study of mRNA-1010 Seasonal Influenza Vaccine in AdultsNCT05415462results2024-09-24Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Day 29, as Measured by Hemagglutination Inhibition (HAI) Assay for Vaccine-matched Influenza A and B Strains | Phase 3 | Completed | Biological: mRNA-1010, Fluarix Tetra | Seasonal Influenza | 6,102 | 2022-06-06 | 2023-09-04actual | — | 2024-09-24 |
| PFE | Pfizer | $155.3B | This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.NCT05858450results2024-09-20observationalNumber of Participants With All Cause Hospitalization Visits: 18-64 Years Old | — | Completed | Biological: Comirnaty, Quadrivalent Influenza Vaccine | Influenza, Human, COVID-19 | 3,442,996 | 2023-05-05 | 2023-05-12actual | — | 2024-09-20 |
| VIR | Vir Biotechnology, Inc. | $1.6B | A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza ANCT05567783results2024-09-19Percentage of Participants With Protocol-defined Influenza-like Illness (ILI) With Confirmed Influenza A (by Reverse Transcription Polymerase Chain Reaction [RT-PCR]) | Phase 2 | Terminatedsponsor's stated reason: VIR-2482 1200 mg did not demonstrate efficacy versus placebo in the primary analysis of the primary endpoint | Biological: VIR-2482 (450 mg), VIR-2482 (1200 mg), Placebo | Influenza A | 2,977 | 2022-10-30 | 2023-05-05actual | — | 2024-09-19 |
| NVAX | Novavax | $1.3B | A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination VaccineNCT05519839Part 1 and Part 2 : Number of participants with solicited local and systemic Adverse Events (AEs) | Phase 2 | Completed | Drug: qNIV Vaccine with Matrix-M Adjuvant, Influenza Vaccine, CIC Vaccine with Matrix-M Adjuvant, SARS-CoV-2 rS Vaccine with Matrix-M Adjuvant · Other: Placebo Comparator | COVID-19, Influenza | 1,579 | 2022-12-30 | 2023-07-25actual | — | 2024-07-16 |
| ALT | Altimmune, Inc. | $578M | Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAXNCT03232567results2019-04-11Number of Treatment-Emergent Adverse Events in Participants [Safety and Tolerability] | Phase 2 | Completed | Biological: NasoVAX | Influenza | 60 | 2017-09-18 | 2018-03-07actual | — | 2024-04-30 |
| TMO | Thermo Fisher Scientific, Inc | $217.8B | Project STARFISH - PRJ0002679NCT05727202observationalPrimary Endpoint | — | Completed | Diagnostic test: The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel | SARS-CoV-2 Infection, Influenza A, Influenza Type B, RSV Infection | 1,909 | 2023-02-20 | 2024-04-02actual | — | 2024-04-30 |
| EBS | Emergent BioSolutions | $239M | Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1NCT01006798Safety, defined as the frequency and severity of vaccine-related reactogenicity events and reported AEs | Phase 1 | Completed | Other: Placebo · Biological: Ad4-H5-Vtn, Sanofi Pasteur Influenza Virus Vaccine, H5N1 | Bird Flu, Influenza | 166 | Oct 2009 | Sep 2011actual | — | 2024-03-18 |
| EBS | Emergent BioSolutions | $239M | Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza ANCT03315104results2020-10-05Frequency Counts and Percentage of Subjects With Adverse Events | Phase 2 | Completed | Biological: FLU-IGIV · Other: Placebo for FLU-IGIV | Influenza A H3N2, Influenza A H1N1 | 65 | 2017-11-17 | 2019-06-17actual | — | 2024-03-18 |
| PFE | Pfizer | $155.3B | A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against InfluenzaNCT05052697results2024-03-12Percentage of Participants Reporting Local Reactions After Vaccination 1: Substudy A | Phase 1/2 | Completed | Biological: mIRV, bIRV AB, qIRV, QIV, bIRV AA, bIRV BB | Influenza, Human | 1,158 | 2021-09-13 | 2023-01-27actual | — | 2024-03-12 |
| MRNA | ModernaTX, Inc. | $25.1B | A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years OldNCT05585632Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) | Phase 1 | Completed | Biological: mRNA-1010, mRNA-1345, mRNA-1273.214, mRNA-1045, mRNA-1230 | SARS-CoV-2, Influenza, RSV | 392 | 2022-10-14 | 2024-02-28actual | — | 2024-03-08 |
| PFE | Pfizer | $155.3B | A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza.NCT06163677observationalPrevalence, Severity, and duration of SARS-CoV-2 symptoms | — | Withdrawnsponsor's stated reason: Study cancelled due to change in feasibility. | Biological: COVID-19 Vaccine | COVID-19, Coronavirus Disease 2019, Influenza | 0 | 2024-01-17 | 2024-01-17actual | — | 2024-03-01 |
| MRNA | ModernaTX, Inc. | $25.1B | A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years OldNCT05375838results2024-02-28Number of Participants With Solicited Local and Systemic Adverse Reaction (ARs) | Phase 1/2 | Completed | Biological: mRNA-1073, mRNA-1010, mRNA-1273, Placebo | SARS-CoV-2, Influenza | 550 | 2022-05-13 | 2022-12-29actual | — | 2024-02-28 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy AdultsNCT05333289results2024-02-01Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) | Phase 1/2 | Completed | Biological: mRNA-1030, mRNA-1020, mRNA-1010, Active Comparator | Seasonal Influenza | 572 | 2022-04-06 | 2022-11-22actual | — | 2024-02-01 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy AdultsNCT04956575results2023-10-27Number of Participants With Solicited Local and Systemic ARs | Phase 1/2 | Completed | Biological: mRNA-1010, Placebo, Active Comparator | Seasonal Influenza | 885 | 2021-07-06 | 2022-09-27actual | — | 2023-10-27 |
| NVAX | Novavax | $1.3B | Phase 3 Pivotal Trial of NanoFlu™ in Older AdultsNCT04120194results2023-05-06HAI Antibody Responses for Vaccine Homologous Influenza Strains Expressed as Ratio of Geometric Mean Fold Ratio (GMFR) | Phase 3 | Completed | Biological: NanoFlu, Fluzone Quadrivalent | Influenza, Human | 2,654 | 2019-10-14 | 2020-10-29actual | — | 2023-05-06 |
| SNY | Sanofi | — | Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 MonthsNCT05832333observationalOccurence of solicited injection site or systemic reactions | — | Completed | Biological: VaxigripTetra® | Influenza | 682 | 2019-10-05 | 2022-02-07actual | — | 2023-04-27 |
| NVAX | Novavax | $1.3B | Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)NCT03293498results2022-12-21Number of Participants With All Adverse Events (AEs), Medically Attended Adverse Events (MAAEs), Serious Adverse Events (SAEs), and Significant New Medical Conditions (SNMCs). | Phase 1/2 | Completed | Biological: NanoFlu, Fluzone HD - Day 0, Fluzone HD - Day 21 · Other: Saline - Day 21 | Influenza | 330 | 2017-09-18 | 2018-03-14actual | — | 2022-12-21 |
| NVAX | Novavax | $1.3B | Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older AdultsNCT03658629results2022-11-04Number of Subjects With Adverse Events (AEs) | Phase 2 | Terminatedsponsor's stated reason: This study was terminated 182 days after initial dosing. | Biological: NanoFlu (Quad-NIV), Fluzone HD, Flublok Quadrivalent, Influenza Vaccine · Other: Matrix-M Adjuvant, Placebo | Influenza, Human | 1,375 | 2018-09-24 | 2019-04-26actual | — | 2022-11-04 |
| 068270.KS | Celltrion | $30.7B | A Study to Evaluate the Efficacy and Safety of CT-P27 in Acute Uncomplicated Influenza A InfectionNCT03511066results2022-10-31Time to Resolution of Influenza Symptoms and Fever | Phase 2 | Terminatedsponsor's stated reason: CT-P27 2.2 is inactivated | Drug: CT-P27 90 mg/kg, CT-P27 45 mg/kg, Placebo | Influenza A | 228 | 2016-12-09 | 2018-03-09actual | — | 2022-10-31 |
| VXRT | Vaxart | $124M | A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu VaccineNCT02918006results2022-10-06Number of Subjects With Influenza-like Clinical Illness and Laboratory Confirmed Infection Post Challenge With a Homologous A Strain Influenza Virus | Phase 2 | Completed | Biological: VXA-A1.1, Fluzone® · Other: Placebo Tablets, Saline Solution for Placebo IM Injection | Influenza | 179 | 2016-08-31 | 2017-08-08actual | — | 2022-10-06 |
| VIR | Vir Biotechnology, Inc. | $1.6B | Study of VIR-2482 in Healthy VolunteersNCT04033406Number of participants with treatment-emergent adverse events. | Phase 1 | Completed | Drug: VIR-2482, Placebo | Influenza A | 100 | 2019-08-26 | 2021-11-01actual | — | 2022-06-09 |
| SNY | Sanofi | — | Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and AboveNCT05406180observationalNumber of participants with solicited injection site or systemic reactions | — | Completed | Biological: VaxigripTetra inj. | Influenza | 675 | 2018-10-10 | 2019-12-27actual | — | 2022-06-06 |
| SNY | Sanofi | — | Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 YearsNCT03344029Summary of Geometric Mean Titers (GMTs) of Each of the Three Strains of TIV Antibodies Following a Single Dose of SP Shz TIV or Hualan TIV | Phase 4 | Completed | Biological: SP Shz TIV, Hualan TIV | Influenza, Flu | 1,600 | 2017-11-03 | 2018-05-22actual | — | 2022-04-25 |
| MRNA | ModernaTX, Inc. | $25.1B | Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult SubjectsNCT03076385Types, frequency, and severity of serious adverse events (SAE), adverse events of special interest (AESI), and adverse events considered related to study drug | Phase 1 | Completed | Biological: VAL-506440 · Other: Placebo | Influenza | 201 | Dec 2015 | Oct 2018actual | — | 2022-04-22 |
| SNY | Sanofi | — | Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlokNCT00539981results2021-02-15Number of Participants Reporting Solicited Injection Site (Local) Reactions | Phase 3 | Completed | Biological: FluBlok®, Placebo | Influenza | 4,648 | 2007-09-15 | 2008-05-28actual | — | 2022-04-06 |
| AAPL | Apple Inc. | $4.52T | Apple Respiratory StudyNCT04912180observationalSymptomatic individuals that self-report ARI and have a laboratory-confirmed positive test for SARS-CoV-2 and/or influenza within 72 hours | — | Terminatedsponsor's stated reason: Study endpoints no longer feasible. | — | Acute Respiratory Infection, Coronavirus Infection, Influenza | 108 | 2021-04-06 | 2021-06-09actual | — | 2021-07-14 |
| BRNS | Barinthus Biotherapeutics | $25M | Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in AdultsNCT03880474results2021-04-26Number and Percentage of Participants With Laboratory Confirmed Influenza Using Reverse Transcription Polymerase Chain Reaction (RT-PCR). | Phase 2 | Terminatedsponsor's stated reason: The trial is being stopped for futility. Season 2 cancelled. | Biological: MVA-NP+M1 · Drug: Saline | Influenza | 2,364 | 2019-03-18 | 2019-10-15actual | — | 2021-04-26 |
| NVS | Novartis | — | Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly SubjectsNCT00841763results2013-01-18Number of Subjects With at Least One Reactogenicity Sign After Two Doses of the Adjuvanted Pandemic Influenza Vaccine. | Phase 3 | Completed | Biological: Placebo (PL), Trivalent influenza virus vaccine (TIV), Adjuvanted monovalent influenza virus vaccine (aH5N1), Adjuvanted trivalent influenza virus vaccine (aTIV) | Pandemic Influenza Disease | 3,647 | Oct 2008 | Apr 2009actual | — | 2021-04-23 |
| BCRX | BioCryst Pharmaceuticals | $2.5B | Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated InfluenzaNCT02369159results2021-03-23Safety and Tolerability, as Measured by the Number of Participants Experiencing Adverse Events. | Phase 3 | Completed | Drug: Peramivir, Oseltamivir | Influenza | 137 | 2015-03-11 | 2019-10-28actual | — | 2021-03-23 |
| BCRX | BioCryst Pharmaceuticals | $2.5B | Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated InfluenzaNCT02635724results2021-03-23Safety and Tolerability, as Measured by the Number of Adverse Events. | Phase 3 | Completed | Drug: Peramivir | Influenza | 74 | Dec 2015 | Apr 2018actual | — | 2021-03-23 |
| BRNS | Barinthus Biotherapeutics | $25M | Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge ModelNCT03883113results2021-03-18Degree of Nasopharyngeal Viral Shedding as Determined by Quantitative Polymerase Chain Reaction qPCR | Phase 2 | Completed | Biological: MVA-NP+M1, Saline, H3N2 (A/Belgium/2417/2015) | Influenza | 145 | 2019-06-03 | 2019-12-16actual | — | 2021-03-18 |
| BCRX | BioCryst Pharmaceuticals | $2.5B | Intramuscular Peramivir in Subjects With Uncomplicated Acute InfluenzaNCT00610935results2021-03-17The Time to Alleviation of Clinical Signs and Symptoms of Influenza | Phase 3 | Terminatedsponsor's stated reason: This study was terminated for administrative reasons. | Drug: Peramivir, Placebo | Influenza | 82 | Jan 2008 | Feb 2008actual | — | 2021-03-17 |
| MRNA | ModernaTX, Inc. | $25.1B | Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult SubjectsNCT03345043Frequency of solicited AEs (local and systemic reactogenicity events) | Phase 1 | Completed | Biological: VAL-339851 · Other: Placebo | Influenza | 156 | 2016-05-11 | 2018-08-13actual | — | 2021-01-11 |
| 068270.KS | Celltrion | $30.7B | A Study to Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge ModelNCT02071914results2020-03-16Viral Load AUC (Day 1 to Day 9) by Nasopharyngeal Swab Quantitative PCR | Phase 2 | Completed | Drug: CT-P27, Placebo | Influenza A | 81 | 2014-02-15 | 2014-05-19actual | — | 2020-04-08 |
| 4507.T | Shionogi | $15.7B | Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza ComplicationsNCT02949011results2019-11-06Time to Improvement of Influenza Symptoms | Phase 3 | Completed | Drug: Baloxavir Marboxil, Placebo to Baloxavir Marboxil, Oseltamivir, Placebo to Oseltamivir | Influenza | 2,184 | 2017-01-11 | 2018-04-12actual | — | 2019-11-19 |
| 4507.T | Shionogi | $15.7B | A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With InfluenzaNCT02954354results2018-12-14Time to Alleviation of Symptoms in Participants Randomized to Baloxavir or Placebo | Phase 3 | Completed | Drug: Baloxavir Marboxil, Placebo to Baloxavir Marboxil, Oseltamivir, Placebo to Oseltamivir | Influenza | 1,436 | 2016-12-08 | 2017-04-04actual | — | 2019-05-08 |
| ALT | Altimmune, Inc. | $578M | Immune Response Following Seasonal Influenza VaccinationNCT03163342results2019-04-26HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain | Phase 4 | Completed | Biological: Licensed seasonal influenza vaccine | Influenza | 20 | 2017-05-08 | 2017-11-21actual | — | 2019-04-26 |
| 4568.T | Daiichi Sankyo Co., Ltd. | $31.7B | A Multinational Phase III Study of CS-8958 (MARVEL)NCT00803595results2011-11-22Time to Alleviation of Influenza Illness | Phase 3 | Completed | Drug: CS-8958, CS-8958, oseltamivir phosphate | Influenza, Human | 1,002 | Nov 2008 | Mar 2009actual | — | 2019-01-09 |
| BRNS | Barinthus Biotherapeutics | $25M | Improved Novel VaccIne CombinaTion InflUenza StudyNCT03300362Number of days with moderate or severe influenza-like symptoms | Phase 2 | Terminatedsponsor's stated reason: Change to recommended season flu vaccine in UK | Drug: Seasonal influenza vaccine, MVA-NP+M1, Sodium chloride | Influenza | 862 | 2017-10-13 | 2018-10-31actual | — | 2018-11-23 |
| 6988.T | Nitto Denko Corporation | $14.8B | Evaluation of the Safety and Immunogenicity of a Sublingual Influenza Vaccine NSV0001 in Healthy Male VolunteersNCT02955030Number of subjects with local and systemic reactions and subjects reporting one or more adverse events | Phase 1 | Completed | Biological: NSV0001, Influenza HA vaccine "Biken HA", Placebo | Influenza | 90 | Oct 2016 | Mar 2017actual | — | 2017-09-18 |
| VXRT | Vaxart | $124M | Safety Study of an Oral Vaccine to Prevent Seasonal InfluenzaNCT01688297Safety of an oral vaccine tablet as measured by reported solicited (reactogenicity) and unsolicited adverse events | Phase 1 | Completed | Biological: VXA-A1.1 Oral Vaccine, VXA Placebo Tablet | Influenza | 61 | Sep 2012 | May 2014actual | — | 2017-05-12 |
| NVS | Novartis | — | Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or OlderNCT00342940CHMP criteria for evaluation of flu vaccines e.g Seroprotection, GMR's and Seroconversion rate at day 21 following vaccination | Phase 2 | Withdrawnsponsor's stated reason: Lack of Vaccine Supplies | Biological: influenza surface antigen inactivated vaccine | Influenza | 0 | Oct 2006 | — | — | 2017-04-20 |
| NVS | Novartis | — | Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 MonthsNCT00649883To evaluate the safety and tolerability of one and two doses of investigational vaccines or active control influenza vaccine in unprimed healthy children aged 6 months to <36 months. | Phase 2 | Completed | Biological: Influenza Trivalent Inactivated vaccines Novartis, Influenza Trivalent Inactivated vaccines | Influenza | 360 | Jan 2008 | Apr 2008actual | — | 2017-04-07 |
| NVS | Novartis | — | Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010NCT00945841Evaluation of antibody response to each influenza vaccine antigen, as measured by haemagglutination inhibition (HI) test on Day 0 and on Day 21 | Phase 3 | Completed | Biological: inactivated split influenza vaccine | Seasonal Influenza | 126 | Jun 2009 | Jun 2009actual | — | 2017-04-07 |
| NVS | Novartis | — | Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly SubjectsNCT00956449Immunogenicity and tolerability of the Flu vaccines is being measured | Phase 2 | Completed | Biological: Seasonal Influenza Vaccine | Influenza, Seasonal Influenza | 126 | Jun 2009 | Jul 2009actual | — | 2017-03-28 |
| NVS | Novartis | — | Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a SubgroupNCT00579345results2011-10-10Number of Randomized Participants Reporting Local and Systemic Reactions. | Phase 3 | Completed | Biological: Cell culture derived seasonal trivalent influenza vaccine (cTIV), Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)., cTIV or eTIV_a, cTIV+PV OR eTIV_a+PV | Influenza | 1,522 | Oct 2007 | Jun 2008actual | — | 2017-01-27 |
| NVAX | Novavax | $1.3B | A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ AdjuvantNCT02078674Assessment of Safety | Phase 1/2 | Completed | Biological: Monovalent Avian Influenza VLP (H7N9), Matrix-M1™ adjuvant, Placebo | Influenza (Pandemic) | 610 | Mar 2014 | Jul 2015actual | — | 2016-09-23 |
| NVAX | Novavax | $1.3B | Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young AdultsNCT02307851Immunogenicity of the quadrivalent VLP vaccine using HAI responses. | Phase 2 | Completed | Biological: Quadrivalent VLP Vaccine, Comparator TIV | Influenza | 400 | Nov 2014 | Jun 2015actual | — | 2016-09-23 |
| SNY | Sanofi | — | Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly SubjectsNCT00551031results2011-11-24Geometric Mean Titers (GMTs) Before and After Vaccination With Fluzone Intradermal or Fluzone High Dose or Fluzone Intramuscular Vaccine. | Phase 2 | Completed | Biological: Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1), Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2), Split, Inactivated, Trivalent Influenza Vaccine (Standard dose), Split, Inactivated, Trivalent Influenza Vaccine (High-dose), Split, Inactivated, Trivalent Influenza Vaccine (Standard dose) | Influenza, Myxovirus Infection | 2,098 | Oct 2007 | Jun 2008actual | — | 2016-05-16 |
| NVS | Novartis | — | Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010NCT00956761results2016-01-27Percentage of Participants Who Achieved Seroconversion or Significant Increase in Single Radial Hemolysis (SRH) Area Against Each of Three Vaccine Strains After One Vaccination of FLUAD | Phase 2 | Completed | Biological: Seasonal Influenza Vaccine (MF59C.1) | Seasonal Influenza | 63 | Jun 2009 | Jun 2009actual | — | 2016-01-27 |
| NVS | Novartis | — | Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly AdultsNCT00973349results2011-05-25Immunogenicity Results After Each Vaccination by Vaccine Group, in Participants 18 to 64 Years of Age | Phase 2/3 | Completed | Biological: MF59-eH1N1_f | Influenza | 2,719 | Sep 2009 | Nov 2009actual | — | 2015-12-07 |
| NVS | Novartis | — | Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and AdolescentsNCT00645411results2013-01-16Geometric Mean Titers of the Cell Culture-derived Vaccine Compared With the Egg-derived Vaccine in 3 to 8 Year-old Children | Phase 2/3 | Completed | Biological: Cell culture-derived influenza subunit vaccine (cTIV), Egg derived influenza subunit vaccine (eTIV), Cell culture-derived influenza subunit vaccine (cTIV), Egg derived influenza subunit vaccine (eTIV) | Influenza | 3,604 | Oct 2007 | Feb 2008actual | — | 2015-11-23 |
| NVS | Novartis | — | A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects.NCT02427750results2015-10-19Percentages of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm^2, Against Each of Three Vaccine Strains After Receiving One Dose of TIV. | Phase 2 | Completed | Biological: Aggripal® | Human Influenza | 126 | Apr 2015 | May 2015actual | — | 2015-10-19 |
| NVS | Novartis | — | Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years OldNCT00464672results2010-05-05Percentage of Subjects With Seroprotection, in Healthy Adults 18 to 64 Years of Age | Phase 3 | Completed | Biological: Influenza virus vaccine, Comparator influenza vaccine | Influenza | 1,893 | Apr 2007 | Jul 2007actual | — | 2015-10-01 |
| NVS | Novartis | — | Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control VaccinesNCT00644059results2014-10-15Number of Subjects (Unprimed) 6 to <36 Months Age With Local and Systemic Reactions After Any Vaccination for All Seasons, Comparison of Adjuvanted Trivalent Influenza Vaccine (aTIV) and Flu Vaccine Control. | Phase 3 | Completed | Biological: Adjuvanted trivalent inactivated subunit influenza vaccine, Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine, Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine | Influenza, Human | 4,902 | Nov 2007 | Apr 2010actual | — | 2015-09-18 |
| PFE | Pfizer | $155.3B | Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza VaccineNCT00521586results2015-04-09Percentage of Participants Achieving at Least 4-fold Increase in Titer for Concomitant Trivalent Inactivated Influenza Vaccine (TIV) Antigens 1 Month After Dose 1 | Phase 3 | Completed | Biological: 13 valent pneumococcal conjugate vaccine, 13 valent pneumococcal conjugate vaccine | Influenza | 1,116 | Sep 2007 | Dec 2013actual | — | 2015-04-09 |
| BCRX | BioCryst Pharmaceuticals | $2.5B | Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.NCT00419263results2015-02-12Time to Alleviation of Symptoms (Kaplan-Meier Estimate) | Phase 2 | Completed | Drug: Peramivir 150 mg, Peramivir 300 mg, Placebo | Influenza | 344 | Jan 2007 | Sep 2007actual | — | 2015-02-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Influenza is matched — 11 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Influenza
- Seasonal Influenza
- Influenza, Human
- Influenza A
- Avian Influenza
- Influenza Immunization
- Influenza (Pandemic)
- Human Influenza
- Influenza A H1N1
- Influenza Type B
- Pandemic Influenza Disease
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Influenza” (a text search, wider than this page)